Interestingly, Niclosamide triggered ROS-mediated JNK activation to promote cell apoptosis under glucose deprivation, suggesting that Niclosamide may be a promising compound for ovarian cancer therapy. This evidence concerns the gene MAPK8 and ovarian cancer.